BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9389515)

  • 1. Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma.
    Lin KH; Zhu XG; Hsu HC; Chen SL; Shieh HY; Chen ST; McPhie P; Cheng SY
    Endocrinology; 1997 Dec; 138(12):5308-15. PubMed ID: 9389515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the molecular mechanism of dominant negative action of mutant thyroid hormone beta 1-receptors: the important role of the wild-type/mutant receptor heterodimer.
    Zhu XG; Yu CL; McPhie P; Wong R; Cheng SY
    Endocrinology; 1996 Feb; 137(2):712-21. PubMed ID: 8593822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line.
    Lin KH; Zhu XG; Shieh HY; Hsu HC; Chen ST; McPhie P; Cheng SY
    Endocrinology; 1996 Oct; 137(10):4073-81. PubMed ID: 8828459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
    Piedrafita FJ; Ortiz MA; Pfahl M
    Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of thyroid hormone action by mutant thyroid hormone receptors, c-erbA alpha 2 and peroxisome proliferator-activated receptor: evidence for different mechanisms of inhibition.
    Meier-Heusler SC; Zhu X; Juge-Aubry C; Pernin A; Burger AG; Cheng SY; Meier CA
    Mol Cell Endocrinol; 1995 Jan; 107(1):55-66. PubMed ID: 7796935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.
    Meier CA; Parkison C; Chen A; Ashizawa K; Meier-Heusler SC; Muchmore P; Cheng SY; Weintraub BD
    J Clin Invest; 1993 Oct; 92(4):1986-93. PubMed ID: 8408652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation.
    Nomura Y; Nagaya T; Tsukaguchi H; Takamatsu J; Seo H
    Endocrinology; 1996 Oct; 137(10):4082-6. PubMed ID: 8828460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The function of retinoid X receptors on negative thyroid hormone response elements.
    Takeda T; Nagasawa T; Miyamoto T; Hashizume K; DeGroot LJ
    Mol Cell Endocrinol; 1997 Apr; 128(1-2):85-96. PubMed ID: 9140079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant negative inhibition by mutant thyroid hormone receptors is thyroid hormone response element and receptor isoform specific.
    Zavacki AM; Harney JW; Brent GA; Larsen PR
    Mol Endocrinol; 1993 Oct; 7(10):1319-30. PubMed ID: 8264663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid hormone receptor monomer, homodimer, and heterodimer (with retinoid-X receptor) contact different nucleotide sequences in thyroid hormone response elements.
    Ikeda M; Rhee M; Chin WW
    Endocrinology; 1994 Oct; 135(4):1628-38. PubMed ID: 7925126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of DNA binding affinity and dimerization properties of wild-type and mutant thyroid hormone receptor beta1.
    Takeda T; Nagasawa T; Miyamoto T; Minemura K; Hashizume K; Degroot LJ
    Thyroid; 2000 Jan; 10(1):11-8. PubMed ID: 10691308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant negative and DNA-binding properties of mutant thyroid hormone receptors that are defective in homodimerization but not heterodimerization.
    Kitajima K; Nagaya T; Jameson JL
    Thyroid; 1995 Oct; 5(5):343-53. PubMed ID: 8563470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
    Ng L; Forrest D; Haugen BR; Wood WM; Curran T
    Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.
    Wong R; Zhu XG; Pineda MA; Cheng SY; Weintraub BD
    Mol Med; 1995 Mar; 1(3):306-19. PubMed ID: 8529109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential sensitivity of thyroid hormone receptor isoform homodimers and mutant heterodimers to hormone-induced dissociation from deoxyribonucleic acid: its role in dominant negative action.
    Zhu XG; McPhie P; Cheng SY
    Endocrinology; 1997 Apr; 138(4):1456-63. PubMed ID: 9075702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in dominant negative activities between mutant thyroid hormone receptors alpha1 and beta1 with an identical truncation in the extreme carboxyl-terminal tau4 domain.
    Nishiyama K; Andoh S; Kitahara A; Natsume H; Mikami T; Genma R; Nakamura H
    Mol Cell Endocrinol; 1998 Mar; 138(1-2):95-104. PubMed ID: 9685218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between thyroid hormone and specific retinoid X receptor subtypes in yeast selectively regulates cognate ligand actions.
    Walfish PG; Yang YF; Ypganathan T; Chang LA; Butt TR
    Gene Expr; 1996; 6(3):169-84. PubMed ID: 9041123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural features of thyroid hormone response elements that increase susceptibility to inhibition by an RTH mutant thyroid hormone receptor.
    Zavacki AM; Harney JW; Brent GA; Larsen PR
    Endocrinology; 1996 Jul; 137(7):2833-41. PubMed ID: 8770904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA.
    Yen PM; Ikeda M; Brubaker JH; Forgione M; Sugawara A; Chin WW
    J Biol Chem; 1994 Jan; 269(2):903-9. PubMed ID: 7904604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone.
    Takeda T; Suzuki S; Liu RT; DeGroot LJ
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2033-40. PubMed ID: 7608251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.